{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:24:26Z","timestamp":1790976266910,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04306"],"award-info":[{"award-number":["17H04306"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["19lm0203088h0001"],"award-info":[{"award-number":["19lm0203088h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11060-019-03388-5","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T05:09:55Z","timestamp":1578028195000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas"],"prefix":"10.1007","volume":"146","author":[{"given":"Ryota","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukina","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kuranari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-1620","authenticated-orcid":false,"given":"Masahiro","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/lary.25976","volume":"126","author":"A Picry","year":"2016","unstructured":"Picry A, Bonne NX, Ding J, Aboukais R, Lejeune JP, Baroncini M, Dubrulle F, Vincent C (2016) Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: a volumetric consideration. Laryngoscope 126:2358\u20132362","journal-title":"Laryngoscope"},{"key":"3388_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00005072-199511000-00004","volume":"54","author":"J Antinheimo","year":"1995","unstructured":"Antinheimo J, Haapasalo H, Sepp\u00e4l\u00e4 M, Sainio M, Carpen O, J\u00e4\u00e4skel\u00e4inen J (1995) Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 54:776\u2013782","journal-title":"J Neuropathol Exp Neurol"},{"key":"3388_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/jns.2002.96.2.0223","volume":"96","author":"VF Mautner","year":"2002","unstructured":"Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg 96:223\u2013228","journal-title":"J Neurosurg"},{"key":"3388_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans DG, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5\u201312","journal-title":"Br J Neurosurg"},{"key":"3388_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","volume":"121","author":"C Seferis","year":"2014","unstructured":"Seferis C, Torrens M, Paraskevopoulou C, Psichidis G (2014) Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg 121:160\u2013166","journal-title":"J Neurosurg"},{"key":"3388_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358\u2013367","journal-title":"N Engl J Med"},{"key":"3388_CR7","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1038\/s41467-019-13640-1","volume":"10","author":"R Tamura","year":"2019","unstructured":"Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M (2019) A VEGF receptor vaccine demonstrates preliminary efficacy in Neurofibromatosis type 2. Nat Commun 10:5758","journal-title":"Nat Commun"},{"key":"3388_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45","journal-title":"BMC Med"},{"key":"3388_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096\u20131103","journal-title":"Nat Med"},{"key":"3388_CR10","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878\u20134886","journal-title":"Blood"},{"key":"3388_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0165-2478(02)00088-3","volume":"83","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T (2002) Microanatomical localization of PD-1 in human tonsils. Immunol Lett 83:215\u2013220","journal-title":"Immunol Lett"},{"key":"3388_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1084\/jem.20022235","volume":"198","author":"Y Iwai","year":"2003","unstructured":"Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T (2003) PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198:39\u201350","journal-title":"J Exp Med"},{"key":"3388_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212:139\u2013148","journal-title":"J Exp Med"},{"key":"3388_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1947601911432334","volume":"2","author":"S Ziyad","year":"2011","unstructured":"Ziyad S, Iruela-Arispe ML (2011) Molecular mechanisms of tumor angiogenesis. Genes Cancer 2:1085\u20131096","journal-title":"Genes Cancer"},{"key":"3388_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","volume":"37","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H (2019) The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol 37:2","journal-title":"Med Oncol"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MAO.0b013e3181d2777f","volume":"31","author":"Z Ahmad","year":"2010","unstructured":"Ahmad Z, Brown CM, Patel AK, Ryan AF, Ongkeko R, Doherty JK (2010) Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otol Neurotol. 31:460\u2013466","journal-title":"Otol Neurotol."},{"key":"3388_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","volume":"34","author":"M de Vries","year":"2013","unstructured":"de Vries M, Briaire-de Bruijn I, Malessy MJ, de Bru\u00efne SF, van der Mey AG, Hogendoorn PC (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34:347\u2013352","journal-title":"Otol Neurotol"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuonc\/noy177","volume":"21","author":"D Lewis","year":"2019","unstructured":"Lewis D, Roncaroli F, Agushi E, Mosses D, Williams R, Li KL, Zhu X, Hinz R, Atkinson R, Wadeson A, Hulme S, Mayers H, Stapleton E, Lloyd SKL, Freeman SR, Rutherford SA, Hammerbeck-Ward C, Evans DG, Pathmanaban O, Jackson A, King AT, Coope DJ (2019) Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro Oncol 21:314\u2013325","journal-title":"Neuro Oncol"},{"key":"3388_CR19","first-page":"30","volume":"22","author":"K Saito","year":"2003","unstructured":"Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30\u201334","journal-title":"Clin Neuropathol"},{"key":"3388_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","volume":"132","author":"A Schulz","year":"2016","unstructured":"Schulz A, B\u00fcttner R, Hagel C, Baader SL, Kluwe L, Salamon J, Mautner VF, Mindos T, Parkinson DB, Gehlhausen JR, Clapp DW, Morrison H (2016) The importance of nerve microenvironment for schwannoma development. Acta Neuropathol 132:289\u2013307","journal-title":"Acta Neuropathol"},{"key":"3388_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, Karajannis MA (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183\u2013190","journal-title":"J Neurooncol"},{"key":"3388_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12022-019-9573-8","volume":"30","author":"R Tamura","year":"2019","unstructured":"Tamura R, Ohara K, Morimoto Y, Kosugi K, Oishi Y, Sato M, Yoshida K, Toda M (2019) PITX2 expression in non-functional pituitary neuroendocrine tumor with cavernous sinus invasion. Endocr. Pathol 30:81\u201389","journal-title":"Endocr. Pathol"},{"key":"3388_CR23","doi-asserted-by":"publisher","first-page":"52423","DOI":"10.18632\/oncotarget.9387","volume":"7","author":"R Tamura","year":"2016","unstructured":"Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2016) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7:52423\u201352435","journal-title":"Oncotarget"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cas.13889","volume":"110","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, Kanai R, Akasaki Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2019) Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 110:499\u2013508","journal-title":"Cancer Sci"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomized controlled trial. Lancet 387:1837\u20131846","journal-title":"Lancet"},{"key":"3388_CR26","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-12-0129","volume":"18","author":"MH Barros","year":"2012","unstructured":"Barros MH, Hassan R, Niedobitek G (2012) Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 18:3762\u20133771","journal-title":"Clin Cancer Res"},{"key":"3388_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12967-018-1460-4","volume":"16","author":"K Takada","year":"2018","unstructured":"Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2018) Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med. 16:86","journal-title":"J Transl Med."},{"key":"3388_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","volume":"26","author":"P Cay\u00e9-Thomasen","year":"2005","unstructured":"Cay\u00e9-Thomasen P, Werther K, Nalla A, B\u00f8g-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98\u2013101","journal-title":"Otol Neurotol"},{"key":"3388_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0028-1096198","volume":"18","author":"DM Dalgorf","year":"2008","unstructured":"Dalgorf DM, Rowsell C, Bilbao JM, Chen JM (2008) Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma. Skull Base 18:377\u2013384","journal-title":"Skull Base"},{"key":"3388_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1227\/01.NEU.0000345342.96663.0A","volume":"65","author":"RJ Komotar","year":"2009","unstructured":"Komotar RJ, Starke RM, Sisti MB, Connolly ES (2009) The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas. Neurosurgery 65:12","journal-title":"Neurosurgery"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253\u2013268","journal-title":"Nat Rev Immunol"},{"key":"3388_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2217\/imt-2018-0006","volume":"10","author":"R Tamura","year":"2018","unstructured":"Tamura R, Tanaka T, Yamamoto Y, Akasaki Y, Sasaki H (2018) Dual role of macrophage in tumor immunity. Immunotherapy 10:899\u2013909","journal-title":"Immunotherapy"},{"key":"3388_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG, Li MO (2014) The cellular and molecular origin of tumor-associated macrophages. Science 344:921\u2013925","journal-title":"Science"},{"key":"3388_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nri2528","volume":"9","author":"JW Pollard","year":"2009","unstructured":"Pollard JW (2009) Trophic macrophages in development and disease. Nat Rev Immunol 9:259\u2013270","journal-title":"Nat Rev Immunol"},{"key":"3388_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI (2015) Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5:202","journal-title":"Front Oncol"},{"key":"3388_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523\u2013532","journal-title":"Nat Rev Immunol"},{"key":"3388_CR37","first-page":"2401","volume":"28","author":"J Wada","year":"2008","unstructured":"Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M, Morisaki T (2008) Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients. Anticancer Res 28:2401\u20132408","journal-title":"Anticancer Res"},{"key":"3388_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539\u2013549","journal-title":"Cancer Res"},{"key":"3388_CR39","doi-asserted-by":"crossref","first-page":"101042831769835","DOI":"10.1177\/1010428317698352","volume":"39","author":"Z Li","year":"2017","unstructured":"Li Z, Liu X, Guo R, Wang P (2017) TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Tumour Biol 39:1010428317698352","journal-title":"Tumour Biol"},{"key":"3388_CR40","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529","journal-title":"BMJ"},{"key":"3388_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495\u2013499","journal-title":"Nature"},{"key":"3388_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S (2014) PD-L1 is a novel direct target of HIF-1\u03b1 and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781\u2013790","journal-title":"J Exp Med"},{"key":"3388_CR43","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.0808698106","volume":"106","author":"AT Argaw","year":"2009","unstructured":"Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 106:1977\u20131982","journal-title":"Proc Natl Acad Sci USA"},{"key":"3388_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0962-8924(99)01578-0","volume":"9","author":"S Tsukita","year":"1999","unstructured":"Tsukita S, Furuse M (1999) Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 9:268\u2013273","journal-title":"Trends Cell Biol"},{"key":"3388_CR45","first-page":"387","volume":"25","author":"S Fukuhara","year":"2010","unstructured":"Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N (2010) Angiopoietin-1\/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 25:387\u2013396","journal-title":"Histol Histopathol"},{"key":"3388_CR46","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1677\/erc.1.01290","volume":"13","author":"S Patiar","year":"2006","unstructured":"Patiar S, Harris AL (2006) Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 13:S61\u201375","journal-title":"Endocr Relat Cancer"},{"key":"3388_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/cas.12691","volume":"106","author":"J Neradil","year":"2015","unstructured":"Neradil J, Veselska R (2015) Nestin as a marker of cancer stem cells. Cancer Sci. 106:803\u2013811","journal-title":"Cancer Sci."},{"key":"3388_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3748\/wjg.v19.i1.42","volume":"19","author":"Y Matsuda","year":"2013","unstructured":"Matsuda Y, Hagio M, Ishiwata T (2013) Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol. 19:42\u201348","journal-title":"World J Gastroenterol."},{"key":"3388_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fimmu.2016.00621","volume":"7","author":"SA Hendry","year":"2016","unstructured":"Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB (2016) The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 7:621","journal-title":"Front Immunol."},{"key":"3388_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans DG, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 19:5\u201312","journal-title":"Br J Neurosurg."},{"key":"3388_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11701-007-0036-8","volume":"1","author":"S McClelland 3rd","year":"2007","unstructured":"McClelland S 3rd, Gerbi BJ, Cho KH, Hall WA (2007) The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy. J Robot Surg. 1:227\u2013230","journal-title":"J Robot Surg."},{"key":"3388_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-0038-1627471","volume":"38","author":"SR Plotkin","year":"2018","unstructured":"Plotkin SR, Wick A (2018) Neurofibromatosis and Schwannomatosis. Semin Neurol 38:73\u201385","journal-title":"Semin Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-019-03388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:07:50Z","timestamp":1650485270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-019-03388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03388-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}